Abstract: A composition is provided suitable for use in a cleaning or washing process. The composition includes an activation agent for activating at least one aqueous sensitive component in use. The composition further includes a water soluble builder component and the activation agent is adsorbed onto a surface of the water soluble builder component.

Abstract: Surface treatment compositions containing selected phosphonic acid compounds are disclosed. The compositions contain major levels of surface-active agents in combination with additive levels of the phosphonic acid compounds, and, in accordance with needs and objectives, conventional optional ingredients and additive agents. The inventive compositions can provide significant performance benefits, among others novel synergies and eminently desirable regulatory and environmental acceptability.

Abstract: The present invention relates to [1] alkali agent-containing particles which are free from deterioration of dissolvability in water and excellent in anti-caking property and which include (a) particles containing an alkali agent and having an average particle size of from 150 to 1000 ?m, and a layer of (b) clay mineral particles exhibiting a water impregnation capacity of 200% by mass or more as calculated according to the following method and having an average particle size of from 1 to 200 ?m, the layer being formed on a surface of the respective particles (a); and [2] a method for suppressing caking of the alkali agent-containing particles including the step of forming a layer of the clay mineral particles (b) on a surface of the respective particles (a): Method for calculation of water impregnation capacity: A dispersion of the clay mineral particles (b) obtained after measuring a swelling power thereof according to JBAS-104-77 is subjected to suction filtration to measure a mass (A) of a residue of the c

Abstract: The present application relates to perfume systems and consumer products comprising new perfumes and/or such perfume systems, as well as processes for making and using such perfume systems and consumer products.

Abstract: A composition and method for delivering a peptide or protein into a cell.

Abstract: Provided herein are peptide modulators of ion channels. Specifically, the peptide modulators comprise the amino acid sequence VEDEC wherein V is valine, E is glutamate, D is aspartate, C is cysteine. In certain embodiments, the modulator is attached to the C-terminal end of Slo1 protein isoform. The present invention also claims conjugations of the first valine that make the peptide modulator more membrane permeable, such as myristoyl moieties and arginine-rich cell penetrating peptides. The present invention contemplates use of the peptide modulators in the treatment of diseases/malfunctions such as epilepsy, chronic pain, migraine, asthma, chronic obstructive pulmonary disease, urinary incontinence, hypertension, erectile dysfunction, irritable bowel syndrome, renal disorders of electrolyte imbalance, and possibly in certain kinds of cancer.

Abstract: The subject invention features methods for predicting whether a subject at risk of developing Acute Respiratory Distress Syndrome (ARDS) will develop ARDS by determining the amount of elafin present in a subject sample, or by determining the ration of elafin:neutrophil elastase in a subject sample. The invention also features methods for monitoring the efficacy of a treatment regimen for ARDS as well as methods of treatment for ARDS. The invention also features methods to determine a subject's predisposition for developing ARDS by determining whether certain genomic polymorphisms are present in the subject's DNA.

Abstract: Provided are compositions and methods for treating bacterial infections. It is demonstrated herein that bacteria cell wall materials stimulate germination of spores of Gram-positive bacteria, and that such activity requires Ser/Thr kinase PrkC. By modulating one or both, spores (which can be antibiotic resistant) can be stimulated or inhibited from germination, which can be exploited in various methods of therapeutic treatment. Also provided is a method of modulating germination of a spore of a Gram-positive bacterium. Also provided is a method of decontaminating an environment.

Abstract: Methods and materials are provided for the production of compositions of erythropoietin protein, wherein said compositions comprise a pre-selected N-linked glycosylation pattern as the predominant N-glycoform.

Abstract: Specially designed GnRH II analogs that are resistant to degradation by peptidases, are disclosed. The GnRH II analogs incorporate D-Arg, D-Leu, D-tBu-Ser, D-Trp, D-Asn or other active D amino acids at position 6 and aza-Gly-amide or other amino acid-amide at position 10. The D-Arg (6)—GnRH II-aza-Gly (10)-amide, D-Asn—GnRH II-aza-Gly (10)-amide, and D-Leu(6)—GnRH II-aza-Gly(10)-amide analogs are also provided, and demonstrate preferential binding to immune system GnRH receptors. These GnRH II analogs or their antibodies may be used in pharmaceutical preparations, and specifically in treatment of various immune system disorders. Antibodies to GnRH II, Applicant's GnRH TI analogs, and GnRH receptors can be used for the detection of GnRH II or the GnRH II analog or the GnRH II receptors as a diagnostic tool and/or to monitor treatment.

Abstract: A method to aid in identifying a familial or sporadic pattern of risk in at least one individual for developing cancer of a mucosal epithelial tissue, the method comprising screening said at least one individual for heterozygosity or homozygosity for a mutation in a gene coding for a Poly-Ig (Fc) receptor or a Poly-Ig-like (Fc) receptor capable of mediating inhibition of cancer cell growth by an immunoglobulin inhibitor. A method of treating an individual so identified includes enhancing the amount of immunoglobulin inhibitor contacting a mucosal epithelial tissue of said individual, and, especially in individuals homozygous for the defective receptor, may also include prophylactic surgery. Other methods include implementation of a risk reduction or prevention program in individuals identified as being at risk.

Abstract: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.

Abstract: Methods of increasing the permeability of corneal epithelium to facilitate the diffusion of agents into the collagen fibrillar network of the stroma are provided. Used in combination, these methods open the epithelium to facilitate diffusion of stabilization molecules into the stroma and dissociate bridging molecules from stromal collagen fibers, thereby priming the collagen fibrillar network for restabilization by stabilization molecules. These methods can be used to increase the effectiveness and longevity of non-invasive corneal reshaping, such as orthokeratology, for correcting myopia, hyperopia and astigmatism.

Abstract: The present invention relates to a process to produce a composition comprising water-soluble peptides and having a Trp/LNAA ratio of more than 0.15, which comprises hydrolyzing lysozyme, preferably hen eggs lysozyme, to prepare a hydrolysate having a DH of between 5 and 45.

Abstract: Described herein are compositions and methods for the treatment of Parkinson's disease (PD) and/or to protect dopaminergic nigrostriatal neuronal cell bodies from 6-OHDA-induced neurotoxicity in a mammal. In various embodiments of the invention, the dopaminergic neuron differentiation factor sonic hedgehog (Shh) and/or its downstream transcription factor target Gli-1 are used in connection with gene therapeutic techniques or direct peptide injection for the aforementioned indications. Kits useful in practicing the inventive method are also disclosed, as are animal models useful for studying various neurodegenerative conditions.

Abstract: The present invention relates to an in vitro method for identifying an individual suffering from or having a predisposition to skin cancer, characterized in that it comprises the step of analysing a biological sample originating from said individual by a) detecting a polymorphism of the MATP/SLC45A2 gene (SEQ ID NO: 1), and/or analysing the expression of the MATP/SLC45A2 gene; to the use, for preparing a composition for the treatment and/or prevention of a skin cancer in an individual, of a compound which specifically increases the expression of the MATP/SLC45A2 gene in a skin cell; and to a method for the selection, in vitro, of a compound capable of being of use in the treatment of skin cancer.

Abstract: Polypeptides that bind to IL-23R including polypeptides having a multimerizing, e.g. trimerizing, domain and a polypeptide sequence that binds IL-23R. The multimerizing domain may be derived from human tetranectin. IL-23R binding polypeptides inhibit activation of IL-23R by native IL-23 and can be used as therapeutics agents for a variety of immune related disorders and cancers. Methods for selecting polypeptides and preparing multimeric complexes are described.

Abstract: A formulation for reducing corneal scarring and related eye conditions, is disclosed. The formulation comprises an effective amount of fibromodulin and can be administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye.

Abstract: The invention provides a modified therapeutic agent, said modified agent comprising three or more membrane binding elements with low membrane affinity covalently associated with the agent which elements are capable of interacting independently and with thermodynamic additivity, with components of cellular or artificial membranes exposed to extracellular fluids wherein at least two membrane binding elements are lipophilic elements, which may be aliphatic acyl groups, which may be selected from the list consisting of Myristoyl, Decanoyl or Hexanoyl.

Abstract: A method for supporting retinal, intestinal, and/or nervous system development in a neonate is provided. The method involves enterally administering arginine-glutamine dipeptide to a neonate.

Abstract: The present invention provides hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.

Abstract: It is an object of the present invention to provide a packaged high-concentration rutin-containing drink suppressed the occurrence of the precipitation though it contains rutin in a high concentration. According to the invention, a packaged high-concentration rutin-containing drink includes rutin and quercetin is provided. The concentration of rutin is in a range from 70 to 1100 ppm and the ratio [(A)/(B)] by weight of (A) rutin to (B) quercetin is 3.7 to 58.0.

Abstract: Provided are methods of designing a putative inhibitor of a 5?-methylthioadenosine/S-adenosylhomocysteine nucleosidase. The methods comprise designing a chemically stable compound that resembles the charge and geometry of the 5?-methylthioadenosine/S-adenosylhomocysteine nucleosidase transition state. Also provided are methods of inhibiting 5?-methylthioadenosine/S-adenosylhomocysteine nucleosidases using the inhibitors found by the above methods.

Abstract: The present invention relates to a novel class of guanine nucleotide analogs which inhibit RelA and Relseq synthetic activity and which possess anti-bacterial activity. The present invention also relates to pharmaceutical compositions that include such compounds, and to methods of use of such compounds or compositions for combating bacteria and treating bacterial infections.

Abstract: The present invention concerns the use of uronic acid saccharide for preventing growth of Enterobacter sakazakii.

Abstract: The invention provides compositions comprising xanthohumol/cyclodextrin complexes that are water soluble and that have increased stability relative to xanthohumol alone.

Abstract: The invention relates to cationic siloxane derivatives for use especially as fungicides and/or antiadhesives. The cationic siloxane derivatives have the formula (I), wherein R1, R2, R3, R4, R4?, R5 and n are as defined in the description.

Abstract: Embodiments herein provide compounds and methods of making and using such compounds for prevention and treatment of multidrug resistant bacteria. In particular, embodiments are directed to anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria.

Abstract: The invention features methods, compositions, and kits for selective inhibition of pain-and itch sensing neurons (nociceptors and pruriceptors) by drug molecules of small molecule weight, while minimizing effects on non-pain-sensing neurons or other types of cells.

Abstract: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.

Abstract: An object of the present invention is to elucidate an analgesic effect as one of new cPA bioactivities and thus to provide a novel analgesic agent. The present invention provides an analgesic agent which comprises a cyclic phosphatidic acid derivative that is one type of phospholipid.

Abstract: Methods and compositions for treating Cryptosporidium parvum related disorders in a mammal are discussed. Several novel tetracycline compounds useful for treating Cryptosporidium parvum related disorders are also included.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The invention relates to a disinfectant which comprises a special combination of biocidal phenols and, where appropriate, phenol derivatives and a keratolytic. The disinfectant is particularly suitable for controlling parasitic protozoa including their persistent forms.

Abstract: This invention discloses (20S,22E)-2-methylene-19-nor-22-ene-1?,25-dihydroxyvitamin D3 analogs, and specifically(20S,22E)-2-methylene-19-nor-22-ene-1?,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits significant vitamin D receptor binding activity and transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent, especially for the treatment or prevention of leukemia, colon cancer, breast cancer, skin cancer or prostate cancer.

Abstract: A topical composition for relief from certain menopausal, peri- and post-menopausal symptoms is disclosed, consisting of a low dosage of progesterone, testosterone and estriol in a pharmaceutically acceptable topical carrier in a weight ratio of from about 1:0.1:0.01 to about 1:0.1:0.02, respectively. In a preferred single dose, the three active ingredients are present as follows: (a) from about 20 to about 35 mg progesterone; (b) from about 2 to about 3.5 mg testosterone; and (c) from about 0.2 to about 0.7 mg estriol. A preferred carrier is cocoa butter, and a preferred single dose form is a vaginal suppository.

Abstract: This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.

Abstract: The subject matter of this application relates to the combination of ciclesonide or an epimer thereof with R,R-formoterol or a salt, or a hydrate of a salt thereof.

Abstract: The present invention provides methods for reducing alcohol drinking behavior in humans and treating acute alcohol poisoning through the use of neutral or negative modulating agents of the neurosteroid sites on GABAA receptors. These agents avoid the unwanted side-effects of opiate antagonists and displays specificity toward the neurosteroid binding sites on GABAA receptors.

Abstract: Compositions and methods for treating obesity in a subject are described. Some embodiments provide methods for administering pharmaceutical formulations including biocompatible emulsifiers in an amount effective to treat obesity. In some embodiments, pharmaceutical formulations include a combination of two or more biocompatible emulsifiers effective to treat obesity.

Abstract: The present invention generally relates to metal complexes of N-heterocyclic carbenes that contain one or more additional active moieties and/or groups therein. In one embodiment, the present invention relates to metal complexes of N-heterocyclic carbenes that contain an anti-fungal and/or anti-microbial moiety and/or group in combination with one or more additional active moieties and/or groups selected from fluoroquinolone compounds or derivatives thereof; steroids or derivatives thereof; anti-inflammatory compounds or derivatives thereof; anti-fungal compounds or derivatives thereof; anti-bacterial compounds or derivatives thereof; antagonist compounds or derivatives thereof; H2 receptor compounds or derivatives thereof; chemotherapy compounds or derivatives thereof; tumor suppressor compounds or derivatives thereof; or C1 to C16 alkyl heteroatom groups where the heterotatom is selected from S, O, or N.

Abstract: The present invention relates to an in vitro method for the diagnosis and treatment guidance of a bacterial infection in patients suffering from an acute ischemic or hemorrhagic stroke, comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from said patient and the correlation of the determined level to the diagnosis of a bacterial infection in said patient.

Abstract: The present application relates to thiazolylidene containing compounds of formula (I) wherein R1, R2, R3, R4, L2 and A are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Abstract: The present invention provides nucleic acid constructs, methods for identifying and validating compounds that increase the inclusion of exon 7 of SMN2 into mRNA transcribed from the SMN2 gene, compounds and pharmaceutical compositions that increase levels of SMN protein produced from the SMN2 gene, and methods for use thereof in treating of SMA.

Abstract: Selected compounds are effective for prophylaxis and treatment of inflammation and inflammatory disorders, such as NIK-mediated disorders. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, inflammation and the like.

Abstract: The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

Abstract: The present invention relates to substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

Abstract: The invention relates methods of treating a patient with locally advanced or metastatic solid tumors with a combination of an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase or PI3K) and an inhibitor of mitogen activated protein kinase (MEK) described herein.

Abstract: The present invention relates to thiophene containing compounds of formula (I) wherein m, n, p, q, r, s, R1, R2, and R3 are as defined in the description. Included also are pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions.

Abstract: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.